Cleveland Clinic | Strategic Alliance Partners

Cleveland Clinic is a nonprofit, multispecialty academic medical center integrating clinical and hospital care with research and education for better patient outcomes and experience. More than 3,900 staff physicians and researchers in 180 medical specialties provide services through 26 clinical and special expertise institutes. Cleveland Clinic comprises a main campus, 11 regional hospitals and more than 150 outpatient locations, with 19 family health centers and three health and wellness centers in northern Ohio, as well as medical facilities in Florida, Nevada, Toronto and Abu Dhabi. Cleveland Clinic is currently ranked as one of the nation’s top hospitals by U.S. News & World Report.

Latest from Cleveland Clinic

Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?

September 30, 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Targeted Therapy Drives Improves Outcomes Throughout Lung Cancer Subtypes

September 24, 2021

The availability of targeted agents for patients with advanced non–small cell lung cancer who harbor mutations in EGFR, RET, MET, and KRAS has not only led to improved outcomes, but provided greater flexibility for treatment-naïve and pretreated populations, with the possibility of enhanced intracranial activity.

Genomic-Adjusted Radiation Dose Is Associated With First Recurrence and Survival in Solid Tumors

September 03, 2021

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

Dr. Stevenson on Ongoing Research Efforts in ES-SCLC

August 23, 2021

James Stevenson, MD, medical oncologist and hematologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

Optimal Sequencing and Treatment Intensity Remain the Focus of Treatment in HER2+ Breast Cancer

August 03, 2021

G. Thomas Budd, MD, discussed the promise of tailored treatment approaches in HER2-positive breast cancer, the utility of the combination of fixed-dose trastuzumab, pertuzumab, and hyaluronidase-zzxf via subcutaneous administration, and how sequencing could be further affected by drug development.

CDK4/6 Inhibitors Show Hints of Activity in Early-Stage HR+/HER2- Breast Cancer

July 12, 2021

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

Pacritinib May Possess the Potential to Address Unmet Needs in Myelofibrosis

June 22, 2021

For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.